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Abstract Human peroxiredoxin 5 is a recently discovered mi-
tochondrial, peroxisomal and cytosolic thioredoxin peroxidase
able to reduce hydrogen peroxide and alkyl hydroperoxides. To
gain insight into peroxiredoxin 5 antioxidant role in cell protec-
tion, we investigated the resistance of yeast cells expressing
human peroxiredoxin 5 in mitochondria or in the cytosol against
oxidative stress induced by paraquat. The herbicide paraquat is
a redox active drug known to generate superoxide anions in
mitochondria and the cytosol of yeast and mammalian cells
leading to the formation of several reactive oxygen species.
Here, we report that mitochondrial and cytosolic human peroxi-
redoxin 5 protect yeast cells from cytotoxicity and lipid peroxi-
dation induced by paraquat.
 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Peroxiredoxins (PRDXs) are enzymes that play an impor-
tant role in eukaryotes and prokaryotes in reducing hydrogen
peroxide (H2O2), organic hydroperoxides (ROOH) and per-
oxynitrite (ONOO3) by the use of reducing equivalents de-
rived from thiol-containing donor molecules such as thiore-
doxin, glutathione, tryparedoxin, alkyl hydroperoxide reduc-
tase subunit F (AhpF) and cyclophilin A [1^5]. Six PRDXs
have been discovered in mammals with distinct subcellular
localizations and a wide tissue distribution. Mammalian
PRDXs have been implicated in the modulation of signaling
cascades leading to cell di¡erentiation, proliferation and im-
mune response but also in direct antioxidant protection (for
review see [6^10]).
Peroxiredoxin 5 (PRDX5), also known as PrxV, AOEB166,
PMP20 or ACR1, is a mammalian thioredoxin peroxidase
that can be addressed to mitochondria, peroxisomes and the
cytosol [11^14]. PRDX5 ortholog in Saccharomyces cerevisiae
is alkyl hydroperoxide reductase 1 (Ahp1p) also named
Ylr109w, PMP20 and cTpxIII [15,16]. Moreover, Ahp1p is
addressed in yeast to peroxisomes and the cytosol [17].
Paraquat is a redox active drug and its toxic e¡ect is
thought to be mediated by reactive oxygen species (ROS)
produced by the enzymatic one-electron reduction of paraquat
at the expense of NADPH or NADH, followed by one-elec-
tron transfer to dioxygen (O2), generating superoxide anion
(Oc32 ) [18]. These reactions are catalyzed in mitochondria by
the outer membrane NADH^cytochrome b5 oxidoreductase
and by the inner membrane NADH^ubiquinone oxidoreduc-
tase [19]. Moreover, paraquat is also reduced by the endoplas-
mic reticulum NADPH^cytochrome P450 oxidoreductase
[19]. ROS generated by paraquat can damage a wide variety
of cellular constituents including DNA, RNA, proteins, sug-
ars and lipids and thereby compromise cell viability [20]. Mi-
tochondria are a main source of ROS and an important target
for oxidative injury. Also, H2O2 induces mitochondrial per-
meability transition and disrupts the mitochondrial membrane
potential. Such conditions in mammalian cells can lead to the
release of cytochrome c from the mitochondria to the cytosol
and can trigger apoptosis by activating pro-caspase 9 [21].
To examine the role of human PRDX5 in the cellular de-
fense against paraquat toxicity, PRDX5 was expressed in the
cytosol and mitochondria of S. cerevisiae. The e¡ects of hu-
man PRDX5 expression on paraquat-induced cytotoxicity in
yeast were then examined and revealed that mitochondrial
and cytosolic PRDX5 protect yeast cells from oxidative stress
induced by paraquat.
2. Materials and methods
2.1. Strains, media and growth conditions
S. cerevisiae strains used in this study were previously described
[22]. ahp1v (leu2-3,112 his3-1 ura3-52 trp1-289 ahp1v : :KANR) and
its corresponding wild-type (WT) (leu2-3,112 his3-1 ura3-52 trp1-
289) were the meiotic segregants obtained by sporulation of CEN.
AHP1/ahp1 [22]. The haploid WT strain was used to prepare genomic
DNA for polymerase chain reaction (PCR) ampli¢cation of AHP1
promoter. Yeast cells were grown aerobically at 30‡C in standard
YPD or SD-URA medium with 2% glucose and amino acids.
2.2. DNA techniques
Standard protocols for nucleic acid manipulation and yeast trans-
formation were used [23]. All DNA constructs were sequenced with
the ABI Prism Big Dye Terminator Cycle Reaction Kit based on the
dideoxy chain termination method (Applied Biosystems).
2.3. Construction of plasmids
The human PRDX5 cDNA (GenBank accession number
NM_012094) coding for the cytosolic form of PRDX5 without the
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mitochondrial presequence [11] under the control of the yeast AHP1
promoter (GenBank accession number Z73281) was obtained by
PCR-mediated overlap extension [24] and cloned into vector YEp24
[25]. The initial two PCRs were performed with primers 5P-AHP1-
BamHI (5P-GTTGTTGGATCCCTTTGGATATTCGTGTTCAAG-
3P) and 3P-AHP1-PRDX5 (5P-CACCTTGATTGGGGCCATGGCM-
GTTTTGTTGTGGTTATTGGTAG-3P) for AHP1 promoter ampli¢-
cation and 5P-AHP1-PRDX5 (5P-CTACCAATAACCACAACAAA-
ACMGCCATGGCCCCAATCAAGGTG-3P) and 3P-PRDX5-SalI (5P-
AATCAGGTCGACCCGCAAACCACAAGTGTTTATTG-3P) for
PRDX5 ampli¢cation. Underlined codons are BamHI and SalI sites.
The switch between AHP1 promoter and PRDX5 cDNA is indicated
(M). The two PCR products, which had a common 43 bp overlap were
used as templates in a PCR-mediated overlap extension with primers
5P-AHP1-BamHI and 3P-PRDX5-SalI to create the amplicon. The
pRDX5 plasmid was obtained by cloning the resulting 1226 bp PCR
product into the BamHI^SalI sites of the vector YEp24 (Fig. 1A).
The same strategy was used as described above to construct the
human PRDX5 cDNA with the mitochondrial presequence under
the control of the yeast AHP1 promoter. Primers 5P-AHP1-PRDX5
and 3P-AHP1-PRDX5 were replaced by primers 5P-AHP1-MITO-
PRDX5 (5P-CTACCAATAACCACAACAAAACMGGTATGGGA-
CTAGCTGGCGTG-3P) and 3P-AHP1-MITO-PRDX5 (5P-CACGC-
CAGCTAGTCCCATACCMGTTTTGTTGTGGTTATTGGTAG-3P),
respectively. The switch between AHP1 promoter and MITO-PRDX5
cDNA is indicated (M). The pMITO-PRDX5 plasmid was obtained by
cloning the resulting 1342 bp PCR product into the BamHI^SalI sites
of the vector YEp24 (Fig. 1B).
The human PRDX5 cDNA in fusion with the sequence coding for
the mitochondrial presequence of yeast cytochrome c oxidase subunit
4 (COX4) (GenBank accession number Z72709) under the control of
the yeast AHP1 promoter was obtained by PCR-mediated overlap
extension and cloned into vector YEp24. The initial three PCRs
were performed with primers 5P-AHP1-BamHI and 3P-AHP1-COX4
(5P-GATTGACGTAGTGAAAGCATMGTTTTGTTGTGGTTATTG-
GTAG-3P) for AHP1 promoter ampli¢cation, 5P-AHP1-COX4 (5P-
CTACCAATAACCACAACAAAACMATGCTTTCACTACGTCAA-
TC-3P) and 3P-MITO-COX4-PRDX5 (5P-CTCCCACCTTGATTGG-
GGCMMAAGCAGATATCTAGAGCTACAC-3P) for MITO-COX4
ampli¢cation and 5P-MITO-COX4-PRDX5 (5P-GTGTAGCTCT-
AGATATCTGCTTMMGCCCCAATCAAGGTGGGAG-3P) and 3P-
PRDX5-SalI for PRDX5 ampli¢cation, respectively. The switch be-
tween AHP1 promoter and COX4 mitochondrial targeting sequence is
indicated (M) as well as between COX4 mitochondrial targeting se-
quence and PRDX5 cDNA (MM). The two ¢rst PCR products, which
had a common 42 bp overlap were used as templates in a fourth PCR
with primers 5P-AHP1-BamHI and 3P-MITO-COX4-PRDX5 to link
AHP1 and COX4 together. The third and fourth PCR products which
had a common 41 bp overlap were used as templates in a PCR-medi-
ated overlap extension with primer 5P-AHP1-BamHI and 3P-PRDX5-
SalI to create the amplicon. The pMITO-COX4-PRDX5 plasmid was
obtained by cloning the resulting 1295 bp PCR product into the
BamHI^SalI sites of the vector YEp24 (Fig. 1C).
2.4. Yeast protein extraction and Western blotting
Yeast protein extraction was performed as previously described
[26]. Protein concentration was determined by the BCA protein assay
(Pierce). Proteins were separated on a standard 12% polyacrylamide
gel, under reducing conditions [23]. Gels were subsequently electro-
blotted onto a nitrocellulose membrane. Rabbit polyclonal anti-
PRDX5 (1:1000) [27], goat anti-rabbit horseradish peroxidase conju-
gate (1:6000) (Dako), and ECL Western blotting detection reagent
(Amersham Pharmacia Biotech) were used. Kodak 1D Image Analysis
Software (Eastman Kodak Company) was used for band quanti¢ca-
tion. Comparison of band intensities of PRDX5 in the di¡erent yeast
strains with those of various amounts of recombinant 6UHis-PRDX5
[28] allowed to estimate the amounts of PRDX5 in ng/Wg total soluble
protein.
2.5. Fluorescence microscopy
Red MitoTracker (Molecular Probes) was used to stain yeast mi-
tochondria. Brie£y, cells were incubated in a bu¡er solution (5% glu-
cose, 10 mM HEPES, 0.5 WM Red MitoTracker) for 30 min at 30‡C
and then washed three times with phosphate-bu¡ered saline (PBS).
Cells were ¢xed with 4% paraformaldehyde in PBS for 1 h in micro-
centrifuge tubes, then washed three times with solution A (1.2 M
sorbitol, 50 mM KPO4, pH 7.0) and resuspended in 500 Wl solution
B (solution A, 0.14 M L-mercaptoethanol, 0.6 mg/ml of zymolase
100 000 T (Sigma) and 0.02% of glusulase (NEN)). After incubation
at 37‡C for 45 min, cells were washed twice with PBS, once with PBS
containing 0.1% Triton X-100 and immersed 30 min in Tris-bu¡ered
saline (0.05 M, pH 7.6) (TBS) with 0.1% Triton X-100 (TBS-T) and
10% non-fat milk. Cells were incubated overnight at 4‡C in TBS-T
containing 1% non-fat milk and 1:200 rabbit polyclonal anti-PRDX5.
Cells were washed three times with TBS-T and incubated with TBS-T
containing 1:50 donkey anti-rabbit secondary antibody (Jackson)
coupled to FITC for 1 h. Finally, cells were washed twice with
TBS-T and once with TBS. Cells were incubated for 1 h at room
temperature. Finally, cells were mounted in Mowiol with DAPI (50
Wg/ml) and examined by £uorescence microscopy.
2.6. Phenotypical analyses
For toxicity assay on solid media, aliquots (3 Wl) from overnight
cultures in SD-URA medium containing 20U103 cells were spotted
on YPD plates containing paraquat (Sigma) at di¡erent concentra-
tions. Plates were monitored after 3 days of incubation at 30‡C.
2.7. Measurement of lipid peroxidation
Lipid peroxidation was quanti¢ed by determination of thiobarbitu-
ric acid-reactive substances (TBARS) as previously described [22].
Fig. 1. Structure of the constructs cloned in yeast expression vector YEp24. A: pPRDX5 ; B: pMITO-PRDX5 ; C: pMITO-COX4-PRDX5.
ATG, initiation codon; TGA, termination codon; PRDX5-poly(A), PRDX5 polyadenylation signal; SQL, PRDX5 peroxisomal targeting se-
quence type 1 Ser-Gln-Leu; Mito. Preseq. PRDX5, human mitochondrial presequence of PRDX5; Mito. Preseq. COX4, yeast mitochondrial
presequence of PRDX5; PROM, promoter of yeast AHP1 gene. The barred arrow in B indicates the non-cleavage of the human mitochondrial
presequence in S. cerevisiae whereas the normal arrow in C indicates the cleavage of the yeast COX4 mitochondrial presequence in S. cerevisiae
(see also Fig. 2).
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2.8. Statistics
The data were analyzed by one-way analysis of variance and the
signi¢cant di¡erences between the controls and the treated groups
were evaluated by post-hoc Newman^Keuls test. A P value 6 0.05
was considered signi¢cant.
3. Results
3.1. Expression and subcellular localization of human PRDX5
in yeast
WT yeast transformed with plasmids pPRDX5 (coding for
the short cytosolic and peroxisomal PRDX5), pMITO-
PRDX5 (coding for the long mitochondrial PRDX5), or pMI-
TO-COX4-PRDX5 (coding for the short PRDX5 in fusion
with S. cerevisiae COX4 mitochondrial targeting sequence)
(Fig. 1) were assayed for PRDX5 expression by immunoblot-
ting (Fig. 2) and immuno£uorescence microscopy (Fig. 3).
Fig. 2 shows a band of 17 kDa corresponding to PRDX5
(lane 1), a band of 22 kDa corresponding to uncleaved
MITO-PRDX5 (lane 2), and two bands of 17 kDa and 22
kDa corresponding, respectively, to cleaved and uncleaved
MITO-COX4-PRDX5 (lane 3). WT yeast and ahp1v mutant
transformed with the empty vector YEp24 did not show any
immunoreactivity (Fig. 2, lanes 4 and 5). Di¡erent amounts of
the 18 kDa recombinant 6UHis-PRDX5 were also loaded in
the gel (Fig. 2, lanes 6^8) [28]. The estimated amounts of
PRDX5 in yeast strains are indicated below the blot (Fig. 2).
Immuno£uorescence microscopy with the anti-PRDX5
antibody [27] in yeast revealed that PRDX5 and MITO-
PRDX5 had a cytosolic localization (Fig. 3A). Human per-
oxisomal targeting sequence Ser-Gln-Leu (SQL) and human
mitochondrial targeting sequence of PRDX5 were not func-
tional in yeast (Fig. 3A). The localization of MITO-COX4-
PRDX5 in yeast showed a reticular pattern which was proven
to be mitochondrial as demonstrated by the staining of these
organelles by Red MitoTracker (Fig. 3B). No immunoreactiv-
ity with anti-PRDX5 antibody was detected in WT yeast and
ahp1v mutant transformed with the empty vector YEp24 (Fig.
3A).
3.2. Lipid peroxidation in yeast
Lipid peroxidation can be followed by measuring in the
medium the levels of malondialdehyde (MDA), which is
mainly produced by decomposition of lipid hydroperoxides
caused by ROS. To determine whether paraquat can cause
lipid peroxidation and whether PRDX5 is able to protect cells
from lipid peroxidation, the amounts of MDA produced by
yeast cells cultured in liquid SD-URA containing paraquat
were measured by the TBARS method. Induction of lipid
peroxidation with 5 and 10 mM paraquat was observed
in WT-pMITO-PRDX5, WT-Vector and ahp1v-Vector. At
5 mM paraquat, lipid peroxidation in WT-pPRDX5 and
WT-pMITO-COX4-PRDX5 was signi¢cantly lower compared
to WT-Vector (Fig. 4). At 10 mM paraquat, only WT-pMI-
TO-COX4-PRDX5 showed signi¢cant lower lipid peroxida-
tion compared to WT-Vector (Fig. 4).
Fig. 2. Expression of human PRDX5 in yeast. Forty Wg of total
soluble protein from cellular extracts from WT-pPRDX5, WT-
pMITO-COX4-PRDX5, WT-Vector and ahp1v-Vector, 120 Wg of
protein from cellular extracts from WT-pMITO-PRDX5 and re-
combinant 6UHis-PRDX5 were loaded in 12% SDS^PAGE (so-
dium dodecyl sulfate^polyacrylamide gel electrophoresis), followed
by Western blotting and immunodetection with polyclonal rabbit
anti-PRDX5. The lanes 6, 7 and 8 contain the indicated amounts of
recombinant 6UHis-PRDX5. Comparison of band intensities of
PRDX5 in the di¡erent yeast strains with those of various amounts
of recombinant 6UHis-PRDX5 allowed to estimate the amounts of
PRDX5 in ng/Wg total soluble protein.
Fig. 3. Subcellular localization of human PRDX5 in yeast. A: WT-pPRDX5, WT-pMITO-PRDX5, WT-Vector and ahp1v-Vector strains were
cultivated in SD-URA medium before immuno£uorescence detection of PRDX5. Panels a^d: localization of human PRDX5; panels e^h:
DAPI staining of nuclei of yeast illustrated in panels a^d. B: WT-pMITO-COX4-PRDX5 strain was cultivated in SD-URA medium before im-
muno£uorescence detection of PRDX5. Panel a: localization of human PRDX5 in yeast cells; panel b: Red MitoTracker staining of mitochon-
dria of yeast cells illustrated in panel a; panel c: DAPI staining of nuclei of yeast cells illustrated in panels a and b. Bars: 10 WM.
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3.3. Human PRDX5 protects yeast cells from paraquat toxicity
Increasing concentrations of paraquat in YPD solid me-
dium produced di¡erent e¡ects on the ¢ve yeast strains. At
concentrations of 8 and 10 mM paraquat, WT-pMITO-
PRDX5, WT-Vector and ahp1v-Vector showed almost no
growth (Fig. 5, lanes 2, 4 and 5) whereas WT-pPRDX5 and
WT-pMITO-COX4-PRDX5 grew (Fig. 5, lanes 1 and 3). The
latter strain was the most resistant to paraquat.
4. Discussion
Recently, more attention was focused on PRDX roles in
mammals as regulators of redox-sensitive signaling due to
their moderate catalytic e⁄ciency compared with those of
classical glutathione peroxidases and catalase [9]. However,
the speci¢c subcellular localization of certain PRDXs in or-
ganelles that are sources of ROS, their abundance in many
di¡erent cell types in mammals and recent ¢ndings that spe-
ci¢c inhibition of individual PRDXs renders cells more sensi-
tive to H2O2 toxicity, lipid peroxidation and apoptosis argue
that mammalian PRDXs are also important protective anti-
oxidant enzymes [14,29,30]. Therefore, to gain insight into
protective antioxidant properties of the recently discovered
human PRDX5, we expressed this thioredoxin peroxidase in
mitochondria and in the cytosol of S. cerevisiae exposed to
oxidative stress induced by the herbicide paraquat, a redox
active drug known to generate Oc32 which can lead to the
formation of H2O2 and hydroxyl radical (cOH) [18].
In mammals, PRDX5 can be addressed to mitochondria,
peroxisomes and the cytosol [11,12,14]. Here, we show that
human mitochondrial PRDX5 with its human mitochondrial
presequence (MITO-PRDX5) and the short cytosolic/peroxi-
somal PRDX5 with its human peroxisomal targeting sequence
(PRDX5) did not enter either into mitochondria or into per-
oxisomes in yeast. On the contrary, both proteins remain in
the cytosol. These results demonstrate that mitochondrial and
peroxisomal targeting sequences of human PRDX5 are not
functional in S. cerevisiae. Furthermore, the lack of cleavage
of the human mitochondrial presequence prevented the pro-
tective activity of PRDX5 against paraquat toxicity possibly
by altering protein conformation. There are several reports in
the literature showing that human mitochondrial presequences
may not be fully functional in yeast [31]. Also, the mammalian
C-terminal peroxisomal targeting sequence Ser-Gln-Leu
(SQL), shared by human PRDX5 and rat pristanoyl^CoA
oxidase, was demonstrated previously to be non-functional
in yeast [32]. Therefore, to address human PRDX5 into yeast
mitochondria, we performed a fusion between short PRDX5
and the S. cerevisiae COX4 mitochondrial presequence
(MITO-COX4-PRDX5). The fusion protein was e¡ectively
targeted into yeast mitochondria and was correctly cleaved
upon internalization into the organelle even if a proportion
of uncleaved protein was still detected in immunoblots.
In this report, we show that the expression of short cyto-
solic PRDX5 and mitochondrial MITO-COX4-PRDX5 con-
ferred higher resistance of yeast cells to paraquat. The toxic
e¡ect of paraquat is believed to be mediated by Oc32 which is
produced following enzymatic reduction of paraquat at the
expense of NADPH or NADH. These reactions occur in mi-
tochondria under the catalytic activity of NADH^cytochrome
b5 oxidoreductase and NADH^ubiquinone oxidoreductase,
and in the endoplasmic reticulum catalyzed by NADPH^cy-
tochrome P450 oxidoreductase [19]. Oc32 generated by the re-
duction of paraquat is then dismutated by mitochondrial
MnSOD and cytosolic Cu/ZnSOD into H2O2. Unlike Oc32 ,
H2O2 is able to di¡use through the cytosol and can generate
the highly toxic cOH by Fenton and Haber^Weiss reactions
[33]. Our results suggest that human cytosolic PRDX5 ex-
pressed in yeast cytosol is able to detoxify H2O2 coming
from the cytosol and probably also from mitochondria. More-
over, human PRDX5 expressed in mitochondria was able to
protect yeast cells even more e⁄ciently than cytosolic PRDX5
from an oxidative stress caused by paraquat as shown by
yeast cultures on plates but also as measured by the level of
lipid peroxidation in liquid cultures. However, although these
results suggest that a better protection is conferred by human
PRDX5 localized in mitochondria, further studies would be
necessary to determine whether this is related to enzymatic
activity as PRDX5 levels were higher in mitochondria than
in the cytosol as demonstrated by immunoblotting. It must be
pointed out that human PRDX5 levels expressed in yeast
were, in our experiments, in the physiological range of mam-
malian PRDXs (ng/Wg total soluble protein) [14].
Interestingly, in this study, we have also shown that para-
quat is equally cytotoxic for the ahp1v mutant and WT yeast
as reported by Park et al. [17]. This lack of paraquat sensi-
tivity for a yeast strain disrupted for the S. cerevisiae ortholog
Fig. 4. Levels of MDA measured by the TBARS method in WT-
pPRDX5, WT-pMITO-PRDX5, WT-pMITO-COX4-PRDX5, WT-
Vector and ahp1v-Vector strains after a 3 h incubation with 0, 5 or
10 mM paraquat in SD-URA medium. The results are the means
VS.E.M. of three independent measurements. *P6 0.05 compared
with WT-Vector; **P6 0.01 compared with WT-Vector.
Fig. 5. Sensitivity of yeast strains to paraquat (PQ). WT-pPRDX5,
WT-pMITO-PRDX5, WT-pMITO-COX4-PRDX5, WT-Vector and
ahp1v-Vector strains were spotted on YPD plates containing di¡er-
ent PQ concentrations. Growth was monitored after 3 days at 30‡C.
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of human PRDX5 could re£ect a di¡erent catalytic e⁄ciency
of Ahp1p compared to human PRDX5. Indeed, recent data
show that PRDX5 reductase activity towards H2O2 is higher
than that of Ahp1p [14,17]. Moreover, an in vitro comparison
of reductase activities of Ahp1p and cTPxI, another yeast
PRDX, showed that whereas Ahp1p activity is speci¢c for
organic peroxides, cTPxI activity is speci¢c for H2O2 [34].
Thereby, H2O2 formed in WT or ahp1v yeast by paraquat
would be mainly reduced by cTPxI, which is a key antioxidant
enzyme to protect yeast cells against intracellular oxidative
stress, especially when induced by H2O2 [17].
In conclusion, we used the yeast S. cerevisiae as a cellular
model to investigate the protective role of human PRDX5
against oxidative stress induced by paraquat. We provide,
for the ¢rst time, evidence that mitochondrial and cytosolic
human PRDX5 are able to protect eukaryotic cells against
highly toxic paraquat.
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